var data={"title":"Ferrous gluconate: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ferrous gluconate: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6191?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ferrous-gluconate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ferrous gluconate: Patient drug information&quot;</a> and <a href=\"topic.htm?path=ferrous-gluconate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ferrous gluconate: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170833\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ferate [OTC];</li>\n      <li>Fergon [OTC] [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170834\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Novo-Ferrogluc</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170863\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Iron Salt</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170837\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Immediate release oral iron products are preferred for treatment of iron deficiency anemia; enteric coated and slow/sustained release preparations are not desired due to poor absorption (Hershko 2014; Liu 2012). Dose expressed in terms of elemental iron; ferrous gluconate contains ~12% elemental iron.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Iron deficiency anemia, prevention in areas where anemia prevalence is &ge;40% (off-label): </b>Oral: Menstruating women (non-pregnant females of reproductive potential): 30 to 60 mg daily for 3 consecutive months in a year (WHO 2016a)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Iron deficiency anemia, treatment of iron deficiency:</b> Oral: 100 to 200 mg daily in 2 to 3 divided doses (Liu 2012; Stoltzfus 1998; WHO 2001)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170853\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=ferrous-gluconate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ferrous gluconate: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dose expressed in terms of elemental iron; ferrous gluconate contains ~12% elemental iron:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Iron deficiency anemia, prevention in areas where anemia prevalence is &ge;40% (off-label; WHO 2016b):</b> Oral: <b>Note: </b>In malaria-endemic areas, iron supplementation in infants and children should be done in conjunction with public health measures to prevent, diagnose and treat malaria.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &ge;6 months to Children &lt;2 years: 10 to 12.5 mg daily for 3 consecutive months in a year</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 years to &lt;5 years: 30 mg daily for 3 consecutive months in a year</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 5 to 12 years: 30 to 60 mg daily for 3 consecutive months in a year</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescent menstruating females (non-pregnant females of reproductive potential): 30 to 60 mg daily for 3 consecutive months in a year</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Iron deficiency anemia, treatment of iron deficiency:</b> Oral: 3 to 6 mg/kg/day in 3 divided doses (Carney 2010; Kliegman, 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170838\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Lower doses (15 to 50 mg elemental iron/day) may have similar efficacy and less GI adverse events (eg, nausea, constipation) as compared to higher doses (eg, 150 mg elemental iron/day) (Rimon 2005). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170819\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fergon: 240 mg [elemental iron 27 mg] [DSC] [contains tartrazine (fd&amp;c yellow #5)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 240 mg [elemental iron 27 mg], 324 mg [elemental iron 38 mg]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ferate: 240 mg [elemental iron 27 mg] [corn free, dairy free, egg free, fragrance free, gluten free, no artificial flavor(s), sodium free, soy free, starch free, sugar free, wheat free, yeast free; contains fd&amp;c blue #1 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ferate: 256 mg [elemental iron 28 mg] [DSC] [gluten free, lactose free, milk free, no artificial color(s), no artificial flavor(s), sodium free, soy free, sugar free, wheat free, yeast free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 324 mg [elemental iron 37.5 mg]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170804\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46576380\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Ferrous gluconate is ~12% elemental iron. Specific amount of elemental iron listed for each dosage form is per the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170822\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Should be administered with water or juice on an empty stomach (Liu 2012). Administration of iron preparations to premature infants with vitamin E deficiency may cause increased red cell hemolysis and hemolytic anemia, therefore, vitamin E deficiency should be corrected if possible.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170821\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Iron-deficiency anemia: </b>Prevention and treatment of iron-deficiency anemias</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170811\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Gastrointestinal: Constipation, darkening of stools, nausea, stomach cramps, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dental discoloration, diarrhea, heartburn</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urine discoloration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Contact dermatitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170825\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to iron salts or any component of the formulation; hemochromatosis, hemolytic anemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170808\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal disease: Avoid in patients with peptic ulcer, enteritis, or ulcerative colitis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood transfusion recipients: Avoid in patients receiving frequent blood transfusions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Anemia in the elderly is often caused by &ldquo;anemia of chronic disease&rdquo; or associated with inflammation rather than blood loss. Iron stores are usually normal or increased, with a serum ferritin &gt;50 ng/mL and a decreased total iron binding capacity. Hence, the &ldquo;anemia of chronic disease&rdquo; is not secondary to iron deficiency but the inability of the reticuloendothelial system to reclaim available iron stores.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. Keep this product out of the reach of children. In case of accidental overdose call the poison control center immediately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Premature infants: Avoid use in premature infants until the vitamin E stores, deficient at birth, are replenished.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Dosage form specific issues: </b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral iron formulations: Immediate release oral iron products are preferred for treatment of iron deficiency anemia; enteric coated and slow/sustained release preparations are not desired due to poor absorption (Hershko 2014; Liu 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Duration of therapy: Administration of iron for &gt;6 months should be avoided except in patients with continuous bleeding or menorrhagia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299323\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170813\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8443&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha-Lipoic Acid: Iron Salts may decrease the absorption of Alpha-Lipoic Acid. Alpha-Lipoic Acid may decrease the absorption of Iron Salts. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the absorption of Iron Salts.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bictegravir: Iron Salts may decrease the serum concentration of Bictegravir.  Management: Bictegravir, emtricitabine, and tenofovir alafenamide can be administered with iron salts under fed conditions, but coadministration with or 2 hours after an iron salt is not recommended under fasting conditions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Iron Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral iron supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<b> Exceptions: </b>Pamidronate; Zoledronic Acid.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefdinir: Iron Salts may decrease the serum concentration of Cefdinir. Red-appearing, non-bloody stools may also develop due to the formation of an insoluble iron-cefdinir complex.  Management: Avoid concurrent cefdinir and oral iron when possible.  Separating doses by several hours may minimize interaction.  Iron-containing infant formulas do not appear to interact with cefdinir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Iron Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimercaprol: May enhance the nephrotoxic effect of Iron Salts.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dolutegravir: Iron Salts may decrease the serum concentration of Dolutegravir.  Management: Administer dolutegravir at least 2 hours before or 6 hours after oral iron. Administer dolutegravir/rilpivirine at least 4 hours before or 6 hours after oral iron salts. Alternatively, dolutegravir and oral iron can be taken together with food.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eltrombopag: Iron Salts may decrease the serum concentration of Eltrombopag.  Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any iron-containing product.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Entacapone: Iron Salts may decrease the serum concentration of Entacapone.  Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ferric Hydroxide Polymaltose Complex: May decrease the serum concentration of Iron Salts. Specifically, the absorption of oral iron salts may be reduced. Management: Do not administer intravenous (IV) ferric hydroxide polymaltose complex with other oral iron salts. Therapy with oral iron salts should begin 1 week after the last dose of IV ferric hydroxide polymaltose complex.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Histamine H2 Receptor Antagonists: May decrease the absorption of Iron Salts.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Isomaltoside: May decrease the serum concentration of Iron Salts. Specifically, absorption of oral iron salts may be reduced. Management: Do not administer intravenous (IV) iron isomaltoside with other oral iron salts. Therapy with oral iron salts should begin 5 days after the last dose of IV iron isomaltoside.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Iron Salts may decrease the serum concentration of Levodopa. Only applies to oral iron preparations.  Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levothyroxine: Iron Salts may decrease the serum concentration of Levothyroxine.  Management: Separate oral administration of iron salts and levothyroxine by at least 4 hours.  Separation of doses is not required with parenterally administered iron salts or levothyroxine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methyldopa: Iron Salts may decrease the serum concentration of Methyldopa. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PenicillAMINE: Iron Salts may decrease the absorption of PenicillAMINE. Only oral iron salts are a concern. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphate Supplements: Iron Salts may decrease the absorption of Phosphate Supplements.  Management: Administer oral phosphate supplements as far apart from the administration of an oral iron salt as possible to minimize the significance of this interaction.<b> Exceptions: </b>Sodium Glycerophosphate Pentahydrate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May decrease the absorption of Iron Salts.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: Iron Salts may decrease the serum concentration of Quinolones.  Management: Give oral quinolones at least several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for levo-, nor-, oflox-, pefloxacin, or nalidixic acid) oral iron salts<b> Exceptions: </b>LevoFLOXacin (Oral Inhalation).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May decrease the absorption of Iron Salts. Iron Salts may decrease the serum concentration of Tetracyclines.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trientine: May decrease the serum concentration of Iron Salts. Iron Salts may decrease the serum concentration of Trientine. Management: Trientine manufacturer recommends avoiding concurrent use with oral iron salts due to the risk for impaired GI absorption of both trientine and the iron salt. Short courses of iron may be used; however, separate administration by at least 2 hours.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170831\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Cereals, dietary fiber, tea, coffee, eggs, and milk may decrease absorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6789289\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">It is recommended that pregnant women meet the dietary requirements of iron with diet and/or supplements in order to prevent adverse events associated with iron deficiency anemia in pregnancy. Treatment of iron deficiency anemia in pregnant women is the same as in nonpregnant women and in most cases, oral iron preparations may be used. Except in severe cases of maternal anemia, the fetus achieves normal iron stores regardless of maternal concentrations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6789292\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Iron is normally found in breast milk. Breast milk or iron fortified formulas generally provide enough iron to meet the recommended dietary requirements of infants. The amount of iron in breast milk is generally not influenced by maternal iron status.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170827\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">May be administered with food to prevent irritation; however, not with cereals, dietary fiber, tea, coffee, eggs, or milk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Elemental iron content of ferrous gluconate: 12%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dietary sources of iron include beans, cereal (enriched), clams, beef, lentils, liver, oysters, shrimp, and turkey. Foods that enhance dietary absorption of iron include broccoli, grapefruit, orange juice, peppers and strawberries. Foods that decrease dietary absorption of iron include coffee, dairy products, soy products, spinach, and tea.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dietary reference intake (IOM 2001): Note:</b> Dose expressed in terms of elemental iron; ferrous gluconate contains ~12% elemental iron.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">0 to 6 months: 0.27 mg/day (adequate intake)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">7 to 12 months: 11 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1 to 3 years: 7 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">4 to 8 years: 10 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">9 to 13 years: 8 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">14 to 18 years: Males: 11 mg/day; Females: 15 mg/day; Pregnant females: 27 mg/day; Lactating females: 10 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">19 to 50 years: Males: 8 mg/day; Females: 18 mg/day; Pregnant females: 27 mg/day; Lactating females: 9 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;50 years: 8 mg/day</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170817\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum iron, total iron binding capacity, reticulocyte count, hemoglobin</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170820\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Therapeutic: Males: 75 to 175 mcg/dL (SI: 13.4 to 31.3 micromole/L); Females: 65 to 165 mcg/dL (SI: 11.6 to 29.5 micromole/L); serum iron level &gt;300 mcg/dL usually requires treatment of overdose due to severe toxicity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170807\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Replaces iron found in hemoglobin, myoglobin, and enzymes; allows the transportation of oxygen via hemoglobin</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170824\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">Onset of action: Hematologic response: Oral: 3-10 days; peak reticulocytosis occurs in 5-10 days, and hemoglobin values increase in &sim;2-4 weeks</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323150\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ferate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">240 (27 Fe) mg (100): $4.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ferrous Gluconate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">240 (27 Fe) mg (100): $2.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">324 (37.5 Fe) mg (100): $3.85</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">324 (38 Fe) mg (100): $6.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170828\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Additiva Ferrum (PL);</li>\n      <li>Ascofer (PL);</li>\n      <li>Biogam Fe (BE);</li>\n      <li>Cromatonferro (IT);</li>\n      <li>Elixir Ferrous Gluconate (ZA);</li>\n      <li>Emoferrina (IT);</li>\n      <li>Eritropiu (MT);</li>\n      <li>Ferglucon (BD);</li>\n      <li>Fergon (AE, AU, GB, IE);</li>\n      <li>Fernore (BE);</li>\n      <li>Ferol (BD);</li>\n      <li>Ferrematos (IT);</li>\n      <li>Ferrlecit (DE, HU);</li>\n      <li>Ferro-Agepha (AT);</li>\n      <li>Ferro-Gradumet (BG);</li>\n      <li>Ferrogluconaat FNA (NL);</li>\n      <li>ferrominerase (DE);</li>\n      <li>Ferronal (IL);</li>\n      <li>Ferronat (BD, LB);</li>\n      <li>Ferrum Verla (DE);</li>\n      <li>Fertinic (AE);</li>\n      <li>Glucofer (JO);</li>\n      <li>Glucoferro (IT);</li>\n      <li>Hemototal (PT);</li>\n      <li>Imperon (ES);</li>\n      <li>Ironax (IT);</li>\n      <li>Ironorm (MT);</li>\n      <li>Losferon (FR);</li>\n      <li>Losferron (DE, IT, LU, NL);</li>\n      <li>Oligostim Fe (BE);</li>\n      <li>Rulofer G (DE);</li>\n      <li>Sustemial (IT);</li>\n      <li>Vitaferro Brause (DE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists, &ldquo;ACOG Practice Bulletin No. 95: Anemia in Pregnancy,&rdquo; <i>Obstet Gynecol</i>, 2008, 112(1):201-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferrous-gluconate-drug-information/abstract-text/18591330/pubmed\" target=\"_blank\" id=\"18591330\">18591330</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baker WF Jr, &ldquo;Iron Deficiency in Pregnancy, Obstetrics, and Gynecology,&rdquo; <i>Hematol Oncol Clin North Am</i>, 2000, 14(5):1061-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferrous-gluconate-drug-information/abstract-text/11005034/pubmed\" target=\"_blank\" id=\"11005034\">11005034</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carney LN, Nepa A, Cohen SS, et al. Parenteral and Enteral Nutrition Support: Determining the Best Way to Feed. In: Corkins MR, Balint J, Bobo E, et al, eds. <i>The A.S.P.E.N Pediatric Nutrition Support Core Curriculum</i>. Silver Spring, MD: American Society of Parenteral and Enteral Nutrition; 2010:440-441.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hershko C and Camaschella C. How I treat unexplained refractory iron deficiency anemia. <i>Blood.</i> 2014;123(3):326-333. doi: 10.1182/blood-2013-10-512624.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferrous-gluconate-drug-information/abstract-text/24215034/pubmed\" target=\"_blank\" id=\"24215034\">24215034</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine), <i>Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc</i>, Washington, DC: National Academy Press, 2001.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Philadelphia, PA: Saunders Elsevier; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipschitz DA, &ldquo;The Anemia of Chronic Disease,&rdquo; <i>J Am Geriatr Soc</i>, 1990, 38(11):1258-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferrous-gluconate-drug-information/abstract-text/2123218/pubmed\" target=\"_blank\" id=\"2123218\">2123218</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liu K, Kaffes AJ. Iron deficiency anaemia: a review of diagnosis, investigation and management. <i>Eur J Gastro Hep</i>. 2012;24(2):109-116.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferrous-gluconate-drug-information/abstract-text/22157204 /pubmed\" target=\"_blank\" id=\"22157204 \">22157204 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marx JJM, &ldquo;Normal Iron Absorption and Decreased Red Cell Iron Uptake in the Aged,&rdquo; <i>Blood</i>, 1979, 53:204-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferrous-gluconate-drug-information/abstract-text/760850/pubmed\" target=\"_blank\" id=\"760850\">760850</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Nutrition During Lactation.&rdquo; Subcommittee on Nutrition During Lactation, Committee on Nutritional Status During Pregnancy and Lactation, Food and Nutrition Board Institute of Medicine, National Academy of Sciences Washington, DC: National Academy Press, 1991. Available at <a href=\"http://www.nap.edu/\" target=\"_blank\">http://www.nap.edu</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Recommendations to Prevent and Control Iron Deficiency in the United States. Centers for Disease Control and Prevention,&rdquo; <i>MMWR Recomm Rep</i>, 1998, 47(RR-3):1-29.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferrous-gluconate-drug-information/abstract-text/9563847/pubmed\" target=\"_blank\" id=\"9563847\">9563847</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rimon E, Kagansky N, Kagansky M, et al, &ldquo;Are We Giving Too Much Iron? Low-Dose Iron Therapy is Effective in Octogenarians,&rdquo; <i>Am J Med</i>, 2005, 118(10):1142-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferrous-gluconate-drug-information/abstract-text/16194646/pubmed\" target=\"_blank\" id=\"16194646\">16194646</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Routine Iron Supplementation During Pregnancy. Review Article. US Preventive Services Task Force,&rdquo; <i>JAMA</i>, 1993, 270(23):2848-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferrous-gluconate-drug-information/abstract-text/8133626/pubmed\" target=\"_blank\" id=\"8133626\">8133626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    United Nations Children&rsquo;s Fund, United Nations University, World Health Organization. Iron Deficiency Anaemia Assessment, Prevention, and Control. A guide for programme managers, 2001. Available at: http://www.who.int/nutrition/publications/en/ida_assessment_prevention_control.pdf.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO): Guideline:<i> Daily Iron Supplementation in Adult Women and Adolescent Girls</i>. Geneva<sub>, </sub>Switzerland: World Health Organization; 2016a. https://www.ncbi.nlm.nih.gov/books/NBK361888/.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferrous-gluconate-drug-information/abstract-text/27195351/pubmed\" target=\"_blank\" id=\"27195351\">27195351</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO): Guideline:<i> Daily Iron Supplementation in Infants and Children</i>. Geneva, Switzerland: World Health Organization; 2016b. https://www.ncbi.nlm.nih.gov/books/NBK362032/.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferrous-gluconate-drug-information/abstract-text/27195348/pubmed\" target=\"_blank\" id=\"27195348\">27195348</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8443 Version 151.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F170833\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F170834\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F170863\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F170837\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F170853\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F170838\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F170819\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F170804\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F46576380\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F170822\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F170821\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F170811\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F170825\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F170808\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299323\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F170813\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F170831\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6789289\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F6789292\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F170827\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F170817\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F170820\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F170807\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F170824\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323150\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F170828\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8443|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ferrous-gluconate-patient-drug-information\" class=\"drug drug_patient\">Ferrous gluconate: Patient drug information</a></li><li><a href=\"topic.htm?path=ferrous-gluconate-pediatric-drug-information\" class=\"drug drug_pediatric\">Ferrous gluconate: Pediatric drug information</a></li></ul></div></div>","javascript":null}